Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Partnership set to make therapies ‘reach patients sooner’
ICON's partnership with Advarra will integrate ICON’s global clinical trial solutions and services with Advarra’s site CTMSs, eISF, and eSource systems, which are already used by more than 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres.
-
ICON teams with Advarra for integrated, AI-driven site network
ICON and Advarra partnership creates an integrated site-centric system that tackles operational bottlenecks and simplifies study execution, addressing sponsors most pressing challenges.
-
ICON, Advarra partnership aims to optimize trials, expand access
ICON and Advarra have partnered to create a connected network of clinical trial sites that integrates ICON’s global trial solutions with Advarra’s site technologies, aiming to streamline study operations, boost efficiency, and expand trial access.
-
ICON partners with Advarra to launch connected site network model
ICON and Advarra have formed a partnership to create a connected, research ready site network that integrates ICON’s clinical trial services with Advarra’s site-facing technology to streamline study startup and trial execution. The collaboration aims to reduce administrative burden, enhance operational visibility, and broaden trial access by standardising workflows for both established and emerging research sites.
-
ICON, Advarra partner on connected site network model
ICON plc and Advarra, a provider of connected, intelligence-powered research technology, have entered a partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials.
-
Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
-
US Pharma and Biotech Summit 2024: Evolving clinical research
In this news article, Applied Clinical Trials reports on ICON CEO Steve Cutler’s discussion at the FT US Pharma and Biotech Summit. Topics addressed included the evolution of the CRO and sponsor relationship, the potential of AI in the clinical development space, and how ICON is helping customers build strong portfolios.
-
Toward more intelligent collaboration: implementing data in partnerships
In this article from Pharmaceutical Outsourcing, Debbie Gilmore, Vice President, Strategic Alliance Management, Ruth Lalor, Vice President, Business Operations and Robert Ellison, Vice President, Data & Applied Analytics, outline how data can play a key role in supporting collaboration and achieving objectives, as strategic partnerships become more important in clinical research outsourcing models.
-
Continued investment key to our success as a life sciences hotspot
In this Irish Times article, Brendan Brennan, CFO, outlines how Ireland’s strong culture of partnership and collaboration, in addition to scientific and technical expertise, has played an important part in the success of the life sciences industry in Ireland.
-
Shaking it up: The partnership paradigm in clinical research
Jeff James, Executive Vice President, Alliance Management, explores how outsourcing methodologies between large pharmaceutical companies and CROs have rapidly evolved across the healthcare and clinical research landscape.
Read the article on page 13 of the December issue of PharmaTimes.
